Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
NVO•Patients who stayed on Novo Nordisk's Wegovy pill lost an average of 6.2% of their body weight over three months, real-world data show. The analysis covered 5,872 adults who took the pill through the Ro telehealth platform.
1. Three-month results
The analysis found that patients who stayed on Novo Nordisk's daily Wegovy pill for three months lost an average of 6.2% of their body weight. Participants lost an average of 6.3 kg from a baseline weight of 103.0 kg; about three-fifths lost at least 5% of their weight, and roughly one in six lost at least 10%.
2. Study participants
The analysis covered 5,872 adults on the Ro telehealth platform who had never taken a weight-loss drug. They started taking the pill between January 5 and February 7, 2026, and remained on it for the full three months.
3. Trial and market context
Novo's chief scientific officer Martin Holst Lange said the real-world results broadly replicated the 5.5% weight loss at 12 weeks seen in the company's late-stage trial. Company presentations earlier this month showed oral treatments represented roughly a third of US obesity prescriptions, with Novo securing over 80% of new oral prescriptions.
